📰 Michael Benatar News
Michael Benatar News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Benatar. Real-time updates on events, politics, business and more.
December 29, 2023
Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.
August 25, 2023
The FDA’s recent accelerated approval of a drug to treat a genetic variant of ALS is not only helping patients diagnosed with the disease, it could be used to slow or even stop the progression before symptoms first appear.
June 22, 2023
Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.
June 1, 2023
- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95% - Adipose Delivery Platform Achieved Single Dose... | June 1, 2023
April 12, 2023
- Event to include presentations on cardiometabolic, pulmonary, and newly announced central nervous system pipeline programs ... | April 12, 2023
February 1, 2022
/PRNewswire/ -- Neuvivo today announced the publication of a paper on its lead candidate drug NP001 for the treatment of ALS in the peer-reviewed journal...
January 13, 2022
The discovery and validation of potential disease progression biomarkers has been one of the top priorities in ALS/MND research. An international
January 13, 2022
An international collaboration led by Flinders University has identified a potential biomarker for amyotrophic lateral sclerosis, also known as Motor Neuron Disease, providing a way to test the effectiveness of future clinical trials.
May 3, 2021
May 4, 2021 The key to optimal treatment of amyotrophic lateral sclerosis (ALS) may be to initiate treatment before symptoms emerge—a difficult, but intriguing, hypothesis that will soon be tested in a clinical trial. That trial, known as ATLAS, will evaluate the best timing to begin treatment with the investigational antisense oligonucleotide tofersen in presymptomatic SOD1 mutation carriers at high risk for ALS. The ATLAS trial will assess levels of the axonal injury marker neurofilament...